← Back to patent-cliff list
Risperidone long-acting injectable (Teva Branded Pharmaceutical)
Tier C — Watch / tradeRisperidone long-acting injectable (Teva Branded Pharmaceutical)
Teva Branded Pharmaceutical Products R&D Inc
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT2A, DRD2
Brand：UZEDY
Indications (approved)：Schizophrenia
Regional status
US
Approved
2023-04-28
EU
Phase III
2018-04-27
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Risperidone long-acting injectable (Teva Branded Pharmaceutical)?
Approved indications include: Schizophrenia.
When does the Risperidone long-acting injectable (Teva Branded Pharmaceutical) patent expire?
No public expiry year is available for Risperidone long-acting injectable (Teva Branded Pharmaceutical) yet; this page updates once verified.
How do I get a quote for Risperidone long-acting injectable (Teva Branded Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27